CTLA4 and neoplasm: The anti-CTLA-4 monoclonal antibody (mAb) is a means of cancer immunotherapy that can enhance the cytotoxicity of T cells against tumor cells by blocking the interaction between CTLA-4 and CD80/CD86 (119).